Knight Therapeutics Inc
- LAST PRICE5.7900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 5.7900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GUD |
|---|---|---|
| 09:34 ET | 1200 | 5.73 |
| 09:45 ET | 200 | 5.73 |
| 09:50 ET | 100 | 5.73 |
| 09:54 ET | 100 | 5.73 |
| 09:57 ET | 100 | 5.73 |
| 09:59 ET | 1600 | 5.725 |
| 10:03 ET | 100 | 5.73 |
| 10:06 ET | 100 | 5.73 |
| 10:10 ET | 100 | 5.73 |
| 10:14 ET | 2500 | 5.76 |
| 10:15 ET | 600 | 5.75 |
| 10:33 ET | 700 | 5.74 |
| 10:35 ET | 500 | 5.72 |
| 10:42 ET | 500 | 5.72 |
| 10:46 ET | 200 | 5.72 |
| 10:50 ET | 800 | 5.72 |
| 10:51 ET | 200 | 5.72 |
| 10:53 ET | 3400 | 5.72 |
| 10:55 ET | 100 | 5.72 |
| 11:02 ET | 100 | 5.72 |
| 11:06 ET | 100 | 5.71 |
| 11:08 ET | 100 | 5.71 |
| 11:15 ET | 2600 | 5.71 |
| 11:20 ET | 100 | 5.71 |
| 11:26 ET | 100 | 5.71 |
| 11:33 ET | 100 | 5.71 |
| 11:36 ET | 11800 | 5.78 |
| 11:40 ET | 2900 | 5.76 |
| 11:49 ET | 100 | 5.73 |
| 11:54 ET | 600 | 5.75 |
| 12:23 ET | 200 | 5.74 |
| 12:30 ET | 200 | 5.75 |
| 12:36 ET | 100 | 5.74 |
| 12:39 ET | 100 | 5.75 |
| 12:41 ET | 100 | 5.73 |
| 12:50 ET | 100 | 5.73 |
| 12:59 ET | 100 | 5.73 |
| 01:03 ET | 100 | 5.73 |
| 01:15 ET | 100 | 5.73 |
| 01:24 ET | 300 | 5.74 |
| 01:37 ET | 100 | 5.73 |
| 02:02 ET | 500 | 5.74 |
| 02:06 ET | 100 | 5.73 |
| 02:54 ET | 900 | 5.75 |
| 02:58 ET | 100 | 5.74 |
| 03:05 ET | 800 | 5.77 |
| 03:18 ET | 100 | 5.76 |
| 03:20 ET | 100 | 5.76 |
| 03:23 ET | 100 | 5.76 |
| 03:27 ET | 100 | 5.76 |
| 03:48 ET | 1500 | 5.79 |
| 03:52 ET | 100 | 5.77 |
| 03:54 ET | 100 | 5.77 |
| 03:56 ET | 100 | 5.79 |
| 03:57 ET | 300 | 5.77 |
| 03:59 ET | 1200 | 5.79 |
Apr 9, 2024
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 7:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
Mar 28, 2024
Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity, from 11:03AM ET on Thursday Mar 28, 2024 by Dow Jones
11:03AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Knight Therapeutics Inc | 578.2M | -35.5x | --- |
Canopy Growth Corp | 993.2M | -0.6x | --- |
TILT Holdings Inc | 15.3M | -0.2x | --- |
OrganiGram Holdings Inc | 269.1M | -0.8x | --- |
High Tide Inc | 244.9M | -6.2x | --- |
Jushi Holdings Inc | 174.9M | -1.9x | --- |
Company Information
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
Contact Information
- Headquarters
- 3400 De Maisonneuve Blvd WMONTREAL, QC, Canada H3Z 3B8
- Phone
- 514-484-4483
- Fax
- 514-481-4116
Executives
- Executive Chairman of the Board
- Jonathan Goodman
- President, Chief Executive Officer, Director
- Samira Sakhia
- Chief Financial Officer
- Arvind Utchanah
- Global Vice President - Commercial
- Jeff Martens
- Global Vice President - Business Development
- Stephani Saverio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $583.4M |
|---|---|
Revenue (TTM) | $328.2M |
Shares Outstanding | 101.2M |
Knight Therapeutics Inc does not pay a dividend. | |
Beta | 0.47 |
EPS | $-0.16 |
Book Value | $7.38 |
P/E Ratio | -35.5x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | 17.4x |
Operating Margin | 0.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
